Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Journal of Pharmacological Sciences

Volumn 130, Issue 3, 2016, Pages 159-169

  Tahara, Atsuo ^a   Takasu, Toshiyuki ^a   Yokono, Masanori ^a   Imamura, Masakazu ^a   Kurosaki, Eiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes; Hyperglycemia; Hyperinsulinemia; SGLT2 inhibitor; Urinary glucose excretion

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; TOFOGLIFLOZIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHARMACOLOGICAL PARAMETERS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; GLUCOSURIA; INSTITUTE FOR CANCER RESEARCH MOUSE; TISSUE DISTRIBUTION;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CANAGLIFLOZIN; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; MALE; MICE, INBRED ICR; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; THIOPHENES; TISSUE DISTRIBUTION;

EID: 84959890006     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2016.02.003     Document Type: Article

References (23)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
2. L. Rossetti Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus Clin Invest Med 18 1995 255 260
3. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin, and et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 31 2008 173 175
4. E.C. Chao SGLT-2 inhibitors: a new mechanism for glycemic control Clin Diabet 32 2014 4 11
5. M.A. Abdul-Ghani, L. Norton, and R.A. DeFronzo Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus Curr Diab Rep 12 2012 230 238
6. E. Kurosaki, and H. Ogasawara Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data Pharmacol Ther 139 2013 51 59
7. M.A. Nauck Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des Devel Ther 11 2014 1335 1380
8. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, and et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 2012 83 90
9. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, Y. Hayashizaki, and et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Naunyn Schmiedeberg's Arch Pharmacol 385 2012 423 436
10. B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 2009 513 519
11. M. Suzuki, K. Honda, M. Fukazawa, K. Ozawa, H. Hagita, T. Kawai, and et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice J Pharmacol Exp Ther 341 2012 692 701
12. Y. Liang, K. Arakawa, K. Ueta, Y. Matsushita, C. Kuriyama, T. Martin, and et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models PLoS One 7 2012 e30555
13. N. Kojima, J.M. Williams, T. Takahashi, N. Miyata, and R.J. Roman Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats J Pharmacol Exp Ther 345 2013 464 472
14. J.J. Liu, T. Lee, and R.A. DeFronzo Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61 2012 2199 2204
15. R.M. Poole, and J.E. Prossler Tofogliflozin: first global approval Drugs 74 2014 939 944
16. T. Sasaki, Y. Seino, A. Fukatsu, M. Ubukata, S. Sakai, and Y. Samukawa Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial Adv Ther 32 2015 319 340
17. T. Kadokura, W. Zhang, W. Krauwinkel, S. Leeflang, J. Keirns, Y. Taniuchi, and et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin Clin Pharmacokinet 53 2014 975 988
18. M. Obermeier, M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, and et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Disp 38 2010 405 414
19. S. Sen, and S. Sinha Canagliflozin (INVOKANA®): a first-in-class anti-diabetic drug J Drug Deliv Ther 3 2013 145 146
20. A.J. Scheen Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor Clin Pharmacokinet 53 2014 213 225
21. S. Uchida, A. Mitani, E. Gunji, T. Takahashi, and K. Yamamoto In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: inhibition kinetics and binding studies J Pharmacol Sci 128 2015 54 57
22. L. Nalysnyk, M. Hernandez-Medina, and G. Krishnarajah Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature Diabetes Obes Metab 12 2010 288 298
23. M. Yamazaki, G. Hasegawa, S. Majima, K. Mitsuhashi, T. Fukuda, H. Iwase, and et al. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers Diabetol Metab Syndr 6 2014 54